The nation of Zimbabwe has rejected a major US healthcare agreement worth 367 million US dollars (£272m) spanning five years over Washington's demand for sensitive data.
This move became public after a government memo from December was disclosed, revealing that Head of State Emmerson Mnangagwa believed the arrangement was "lopsided".
An official representative has since clarified that the US was requesting biological samples for research and commercial gain but was not willing to guarantee the benefits from future medical innovations.
"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the United States had provided over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for continued negotiations to reach a deal acceptable to both sides so the nation's vital HIV programme can continue.
Broader Context
This development follows a similar case in Kenya, where a high court blocked a related health funding agreement after concerns were filed about the safety of citizens' health data.
Since returning to office last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump stated its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to boost transparency and responsibility.
Based on statements, 16 African countries have to date signed similar agreements, representing more than $18.3bn in committed funds.
Specifics of the Rejected Deal
The money for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation would have delivered immense benefits for the people of Zimbabwe, especially the 1.2 million presently on antiretroviral therapy through American-funded programmes," the Ambassador commented.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to share its genetic material and health information indefinitely, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Effectively, our country would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be accessible to our citizens if a future pandemic arise."
National Interest and Global Health
Mangwana further pointed out that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting structures previously established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to manage potential global health emergencies.
"This system is designed to ensure that when a country provides its samples, the benefits – such as medicines and cures – are shared equitably, not monopolised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "are not meant as opposition to America," he added.
"We encourage continued dialogue with our US partners on how future collaboration could be structured in a way that honours the sovereignty and interests of each country."
Medical Community Response
A leading public health body expressed it recognised the government's concerns, but suggested that talks should continue considering much of the nation's Aids initiatives relied on foreign aid.
"In cases where specific concerns arise, including those relating to information security or agreement terms, these can frequently be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the complex tensions between receiving much-needed international aid and safeguarding national sovereignty in an increasingly interconnected world.